H2-CBD
Names | |
---|---|
IUPAC name
2'-Isopropyl-5'-methyl-4-pentyl-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol or 2-(5-methyl-2-(prop-1-en-2-yl)cyclohexyl)-5-pentylbenzene-1,3-diol
| |
Other names
Hydrogenated CBD, HCBD, HCBD, DiHydroCBD, DiHydroCannabidiol
| |
Identifiers | |
Properties | |
C21H32O2 | |
Molar mass | 316.485 g·mol−1 |
Related compounds | |
Related compounds
|
H4-CBD |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
H2CBD (diHydroCBD, partially hydrogenated CBD) are cannabinoids that were first synthesized by Alexander R. Todd in 1940 by catalytic hydrogenation of cannabidiol.[1]
The term "H2CBD" can refer to two different chemical compounds that differ by the site of hydrogenation, either saturated on the cyclohexenyl ring (i.e. 1,2-dihydrocannabidiol using the older terpenoid numbering scheme) or saturated on the isopropenyl side group, which is known as
8,9-dihydrocannabidiol
.
H2CBD, H4-CBD, and 8,9-dihydrocannabidiol have all been referred to as "hydrogenated CBD" which may cause confusion.
Pharmacology
In 2006, it was discovered that 8,9-dihydrocannabidiol binds very weakly to the
CB1 receptor with a binding affinity higher than 1 µM, but has potential anti-inflammatory effects independent of its cannabinoid receptor action.[2]
See also
- THC)
- 4'-Fluorocannabidiol
- 7-Hydroxycannabidiol
- Abnormal cannabidiol
- Cannabidiol dimethyl ether
- Delta-6-cannabidiol
References
- .
- PMID 16451075.